and intensity (amplitude) (50%, 75%, 90% motor threshold). We further examined whether the most effective parameters of SCS would reduce glial cell activation in the spinal cord as a potential underlying mechanism.
METHODS Experimental Procedures
Experiments were performed on adult Sprague-Dawley rats, weighing 250 to 350 g and housed in transparent plastic cages with free access to food and water, in a 12-hour light-dark cycle. All the experimental procedures were approved by the Animal Care and Use Committee at the University of Iowa.
Nerve Injury Model
All rats were anesthetized with 2% to 3% isoflurane. The tibial and common peroneal nerves on 1 limb were tightly ligated with 4-0 silk, and the sural nerve was kept intact, as previously described. 26 The overlying muscle was sutured with 4-0 silk, and the skin was sutured closed with 3-0 silk.
Implantation of Electrode
After nerve injury, a small laminectomy was performed at the level of T13 vertebra, and the SCS lead was inserted epidurally in the rostral direction. The lead was fixed with sutures to the muscle, the wound was sutured in layers, and the lead was tunneled to exit the skin at the base of the neck. 19 We implanted a spinal cord lead designed for use in rats (Medtronic, Minneapolis, MN) that is similar to that used in humans. The proximal end of the lead was tunneled outside the animal for later connection to an external neurostimulator (model # 37021) and programmer (model: #8840) (Medtronic Inc., Minneapolis, MN).
Behavior Tests
Rats were acclimated to the behavior room for 30 minutes followed by acclimation to transparent plastic cubicles on elevated wire mesh floor for 15 minutes. To test for mechanical withdrawal thresholds of the paw, calibrated von Frey filaments (1-402 mN) were applied to the lateral surface bilaterally in the area innervated by the sural nerve. Each filament was applied for approximately 1 second with enough force to bend the filament. Each filament was applied twice, and a positive response was 1 withdrawal. Once a positive response was found, the filament above and below the filament that caused a positive response was tested. Confirmation of mechanical withdrawal threshold was established if there was a positive withdrawal from the filament above and no withdrawal from the filament below. The lowest force that produced a withdrawal was recorded as the mechanical withdrawal threshold. A decrease in mechanical withdrawal threshold is interpreted as cutaneous allodynia in this study.
Immunohistochemistry
We tested for glial cell activation in the spinal cord using immunohistochemistry of astrocyte and microglial markers. Rats were anesthetized with 100 mg/kg sodium pentobarbital and transcardially perfused with heparinized saline (10 U/mL) followed by 4% paraformaldehyde with 15% picric acid. The spinal cords were removed, post fixed in 4% paraformaldehyde for 1 hour, transferred to 30% sucrose solution for 24 hours, and then frozen on dry ice with Tissue Tek OCT (Sakura Finetek, Torrance, CA). Twenty-micrometer cryostat sections were stained onto slides, and all sections in a group were stained simultaneously. All sections were first blocked with 3% normal goat serum for 30 minutes, followed by Avidin-Biotin block (15 minutes/blocker). For sections used for astrocyte staining, sections were incubated overnight with monoclonal antimouse anti-GFAP (Millipore, Billerica, MA, 1:5000, Cat.#MAB360). On the second day, sections were incubated with biotinylated goat antimouse IgG (Invitrogen, Carlsbad, CA, 1:1000, 1 hour), followed by Strep-568 (Invitrogen, Carlsbad, CA, 1:1000, 1 hour). Sections were then incubated overnight in goat antirabbit MCP-1 (Millipore, Billerica, MA, 1:500, Cat.#1834P). On the last day, sections were incubated in biotinylated goat antirabbit IgG (Invitrogen, Carlsbad, CA, 1:1000, 1 hour), followed by Strep-488 (Invitrogen, 1:1000, 1 hour). Slides were covered with Vectashield. For microglia staining, we used immunohistochemistry staining for OX-42, changing the first primary antibody to OX-42 (AbD Serotec, Raleigh, NC, 1:2500, Cat.#MCA275G). Five spinal cord sections (L4-L5) were randomly chosen from each rat and imaged with an Olympus BX-51 fluorescence microscope (Olympus, Center Valley, PA). Images were analyzed for the density of the staining with Image J (National Institutes of Health, Bethesda, MD version 1.24) as we previously described. 27, 28 Specifically, each tissue section was first converted to 8-bit gray scale and then calibrated independently using the "uncalibrated OD" function with pixel values ranging from 0 to 255. A background reading taken from the white matter of the dorsal column in the same section was subtracted from the density reading taken from the gray matter of the same tissue section to control for differences in nonspecific staining. 29 The superficial laminas (I-II) and intermediate and deep dorsal horn (III-VI) were analyzed separately.
Experimental Protocol
Experiment 1 Experiment 1 examined different durations of SCS either 30 minutes or 6 hours. SCS was applied at 4 or 60 Hz frequency and 90% motor threshold intensity (amplitude) (0.35 V) for 4 days. Mechanical withdrawal thresholds were tested before and 2 weeks after spared nerve injury, before and after daily application of SCS for 4 days, and 1, 3, and 9 days after stopping SCS. SCS was applied 2 weeks after spared nerve injury. The following experimental groups were compared: (1) 4 Hz, 30-minute SCS (N = 8), (2) 4 Hz, 6-hour SCS (N = 6), (3) 60 Hz, 30-minute SCS (N =8), (4) 60 Hz, 6-hour SCS (N =6), (5) Sham, 30-minute SCS (N =4), and (6) Sham and 6-hour SCS (N =6). Sham animals were implanted with the neurostimulation hardware and were tethered to the neurostimulator system but did not receive SCS.
Experiment 2
Experiment 2 tested different intensities (amplitude) of SCS: 50%, 75%, or 90% motor threshold. SCS was applied at either 4 or 60 Hz frequency, for 6-hour duration daily for 4 days. Mechanical withdrawal thresholds were tested before www.anesthesia-analgesia.org aNesthesia & aNalgesia and 2 weeks after spared nerve injury, before and after daily application of SCS for 4 days, and 1 day after stopping SCS. SCS began 2 weeks after spared nerve injury. The following experimental groups were compared: (1) 4 Hz, 50% motor threshold (N =8), (2) 4 Hz, 75% motor threshold (N = 8), (3) 60 Hz, 50% motor threshold (N = 8), (4) 60 Hz, 75% motor threshold (N = 8), (5) Sham, 6-hour SCS (N = 8). These data were compared with the groups from Experiment 1, which received 90% motor threshold intensity (amplitude) for 6 hours. Sham animals were implanted with the neurostimulation hardware and were tethered to the neurostimulator system but did not receive SCS.
Experiment 3
Experiment 3 tested the effects of SCS on glial cell activation in the spinal cord using immunohistochemistry of astrocyte and microglial markers. SCS was delivered for 4 days beginning 2 weeks after spared nerve injury as follows: 90% motor threshold intensity (amplitude), 6-hour duration, either 4 or 60 Hz frequency. Animals were divided as follows: (1) naive control for OX-42, or GFAP and MCP-1 (N = 5/marker), (2) 60 Hz SCS for OX-42, or GFAP and MCP-1 (N = 5/marker), (3) 4 Hz SCS for OX-42, or GFAP, and MCP-1 (N = 5/marker).
Statistical Analysis
Analysis of the data was performed using SPSS 13.1 (Statistical Package for the Social Sciences, IBM, Armonk, NY). The effect of nerve injury on withdrawal thresholds was tested with a simple paired t test and is in paragraph 1 of the results. Withdrawal threshold data were normalized using a difference score between thresholds obtained after SCS compared with those before SCS that therefore led to 1 number for each day of treatment (days 1-4). Repeatedmeasures analysis of variance (ANOVA) assessed for differences across time for days 1 to 4 with a post hoc Tukey test to examine for differences among groups. Data were also transformed to an area under the curve for the first 4 days of measures after SCS and analyzed with a 1-way ANOVA with a post hoc Tukey test to examine for differences among groups.
The first hypothesis examined whether longer-duration SCS was more effective than shorter-duration SCS. We used repeated-measures ANOVA to examine difference scores immediately after SCS over the 4 days (days 1-4) using duration (0 [sham], 30 minutes, 6 hours) and frequency (0 [sham], 4 Hz, 60 Hz) as between-subject factors. Post hoc testing with a Tukey test examined for differences among groups. The second hypothesis tested whether higher amplitude SCS produced greater analgesia. We used repeated-measures ANOVA to examine difference scores immediately after SCS over the 4 days using amplitude (intensity) (days 1-4) (0 [sham], 50%, 75%, 90% motor threshold) and frequency (0 [sham], 4 Hz, 60 Hz) as between-subject factors. Post hoc testing with a Tukey test examined for differences among groups. The third hypothesis tested whether there was a carryover effect of TENS examining difference scores between values 24 hours, 3, and 9 days after stopping SCS to those before SCS on day 1. Differences with 4 and 60 Hz SCS were compared with differences from sham SCS with a 1-way ANOVA followed by a Tukey test at each time period.
Post hoc testing between different groups was performed with a Tukey test. The fourth hypothesis examined for differences in the responders and nonresponders. Responders and nonresponders were established based on the mechanical withdrawal threshold response after SCS. Responders were defined as those with an increase in mechanical withdrawal threshold by 2 filaments or more during SCS. 19 A Pearson χ 2 test compared differences between responders and nonresponders by frequency (60 vs 4 Hz) and duration (30 minutes vs 6 hours). The fifth hypothesis examined whether SCS reduced glial cell activation in the spinal cord. The density of immunostaining was analyzed using a 1-way ANOVA followed by post hoc testing with a Tukey test. Data are presented as the mean ± SEM. A P ≤ 0.05 was considered significant.
RESULTS

Spared Nerve Injury Model Induces Hyperalgesia
Before spared nerve injury, baseline mechanical withdrawal threshold averaged 295 ± 18 mN. Two weeks after spared nerve injury, all groups showed a significant decrease in their mechanical withdrawal threshold ipsilaterally, averaging 20 ± 3.2 mN. The contralateral side showed a decrease that averaged 89 ± 4.6 mN, but this was not statistically significant from baseline ( Fig. 1 ).
Longer-Duration SCS Produces Greater Analgesia
After SCS, between-subject comparisons show there was a significant effect for the duration of SCS (F 1,31 = 15.3, P = 0.0001) and frequency of SCS (F 1,31 = 8.1, P = 0.008). There was no interaction between frequency and duration (F 1,31 = 1.6, P = 0.21). Six-hour SCS showed significantly greater analgesia when compared with 30-minute SCS (P = 0.0001) or sham (P = 0.0001); 30-minute SCS was significantly greater than sham SCS (P = 0.0001) ( Fig. 2A ). SCS produced a significant increase in the mechanical withdrawal threshold ipsilaterally after 60 Hz SCS (P = 0.0001) or 4 Hz SCS (P = 0.0001), when compared with sham SCS. The greatest increase in the mechanical withdrawal threshold occurred with 60 Hz SCS delivered for 6 hours at 90% motor threshold. There was a significant increase in withdrawal thresholds after stopping SCS 24 and 3 days after SCS that was reversed by 9 days after SCS. This effect was significant for the group that received 6-hour SCS (P = 0.003) but not 30-minute SCS (P = 0.07). Figure 2B shows the area under the curve for the groups on days 1 to 4.
On day 1, the number of responders (animals that had an increase in their withdrawal thresholds by 2 filaments or more) 19 in the 60 Hz 6-hour SCS group was 100%, compared with 62% in the 60 Hz 30-minute SCS group, 67% in the 4 Hz 6-hour SCS group, and 13% in the 4 Hz 30-minute SCS group. An overall difference was observed among groups (χ 2 = 11.3, P = 0.01).After SCS, there were significantly more responders in the groups receiving 60 Hz (79%) compared with those receiving 4 Hz (36%) (χ 2 = 5.2, P =0.02). Furthermore, there were more responders in the group receiving 6-hour (83%) SCS when compared with 30-minute SCS (37%) (χ 2 = 5.9, P = 0.01).
Greater Intensity (Amplitude) of SCS Produces Greater Analgesia
After SCS, between-subjects comparisons show there was a significant effect for amplitude (intensity) of SCS (F 2,45 = 30.0, P = 0.0001) but not frequency of SCS (F 1, 45 However, there was a significant interaction between frequency and amplitude (F 2,45 = 9.7, P = 0.0001), and post hoc tests show that sham SCS is significantly different from 4 and 60 Hz SCS (P = 0.0001). SCS delivered at 90% motor threshold amplitude produced the largest increase in withdrawal thresholds and was significantly different from 75% (P = 0.0001) and 50% (P = 0.0001) motor threshold SCS and sham SCS (P = 0.0001). Seventy-five percent motor threshold SCS significantly increased withdrawal thresholds when compared with sham SCS (P = 0.0001) and 50% motor threshold SCS (P = 0.0001). Fifty percent motor threshold SCS was similar to sham SCS (P =0.91). There was a significant difference when comparing the 3 intensities as follows: 90% motor threshold >75% motor threshold >50% motor threshold = sham SCS (Fig. 3 ).
SCS Suppressed Spinal Glial Activation in Neuropathic Pain
After SCS, immunohistochemistry was performed to determine whether SCS suppressed glial activation in the spinal dorsal horn in animals with neuropathic pain. Both microglial (OX-42 positive) ( Fig. 4A ) and astrocytic markers (GFAP positive and MCP-1 positive) (Fig. 5, A and B) were significantly increased bilaterally 2 weeks after spared nerve injury. Four days of SCS (4 or 60 Hz, 6 hours, 90% motor threshold) significantly decreased OX-42, GFAP, and MCP-1 (Figs. 4A, 5, A and B) . The density of the microglia marker OX-42 was increased bilaterally in laminae I-II 2 weeks after spared nerve injury when compared with naive controls (ipsilateral P = 0.01; contralateral P = 0.008). Both 60 and 4 Hz SCS significantly decreased OX-42 staining in the superficial laminae bilaterally when compared with sham SCS: 60 Hz (ipsilateral P = 0.0001; contralateral P = 0.001); 4 Hz (ipsilateral P = 0.0001; contralateral P = 0.003). In laminae III-V, the density of immunoreactivity for OX-42 was also increased after spared nerve injury both ipsilaterally (P = 0.001) and contralaterally (P = 0.001) when compared with naive controls. SCS significantly decreased the OX-42 staining in the deep dorsal horn when compared with sham SCS: 60 Hz (ipsilateral P = 0.005; contralateral P = 0.004); 4 Hz group (ipsilateral P = 0.005; contralateral P = 0.004) (Fig. 4B) .
For astrocyte markers, we examined GFAP and MCP-1. In animals with spared nerve injury, significant increases in the density of immunoreactivity for GFAP and MCP-1 occurred in laminae I-II for both the ipsilateral (GFAP P = 0.0001; MCP-1 P = 0.007) and the contralateral (GFAP P = 0.001; MCP-1 P = 0.03) sides when compared with naive animals. SCS reduced the spared nerve injury-induced increased immunoreactivity for GFAP both ipsilaterally (60 Hz P = 0.0001; 4 Hz P = 0.0001) and contralaterally (60 Hz P = 0.002; 4 Hz P = 0.0001) in the superficial laminae. Similarly, statistically significant increases in the density of GFAP and MCP-1 in laminae I-II and III-V occurred after spared nerve injury, and these increases were reduced by both 60 and 4 Hz SCS laminae I-II ipsilaterally (GFAP: control vs spared nerve injury P = 0.0001, spared nerve injury vs 60 Hz P = 0.001, spared nerve injury vs 4 Hz P = 0.002; MCP-1: control vs spared nerve injury P = 0.007, spared nerve injury vs 60 Hz P = 0.002, spared nerve injury vs 4 Hz P = 0.843) and laminae I-II contralaterally (GFAP: control vs spared nerve injury P = 0.001, spared nerve injury vs 60 Hz P = 0.001, spared nerve injury vs 4 Hz P = 0.123; MCP-1: control vs spared nerve injury P = 0.003, spared nerve injury vs 60 Hz P = 0.001, spared nerve injury vs 4 Hz P = 0.269) (Fig. 5, C and D) .
DISCUSSION
In the present study, we demonstrated that longer-duration SCS (6 hours) produces greater analgesia than shorterduration SCS (30 minutes); that 90% motor threshold intensity (amplitude) is better than 75% motor threshold, and both are better than 50% motor threshold or sham SCS. Furthermore, both 60 and 4 Hz SCS decrease activation of glial cells (microglia and astrocytes) in the spinal cord, suggesting that SCS reduces central excitability. 
Effectiveness of SCS Depends on Intensity (Amplitude)
SCS is generally delivered both clinically and in experimental studies below motor threshold. Most of these use intensities (amplitudes) approximately two-thirds motor threshold to produce analgesia. 19, [30] [31] [32] [33] [34] The current study showed an intensity-dependent analgesia with the greatest analgesia at 90% motor threshold and no analgesia at 50% motor threshold.
Similarly, intensity-dependent reductions in inflammationinduced hyperalgesia or pain thresholds are observed with TENS in both animal and human subjects, respectively. 35, 36 Higher intensities (amplitudes) of SCS and TENS produce a longer and greater magnitude of analgesia with greater amplitudes, 18, 24, 25, 35 and greater intensities (amplitudes) of SCS correlate with longer duration and magnitude of pain relief in rats. 18, 20, 30 Thus, intensity-dependent analgesia occurs www.anesthesia-analgesia.org aNesthesia & aNalgesia for both SCS and TENS, suggesting that intensity (amplitude) is a key factor in stimulation-produced analgesia.
SCS Is More Effective with Longer-Duration Stimulation
We showed a small but significantly larger reduction in hypersensitivity with 6 hours of stimulation, particularly with 60 Hz SCS. Previous studies clearly show reductions with stimulation durations as little as 5 minutes with the most of studies showing good reductions in hypersensitivity with 30 minutes to 1 hour of SCS. 19, [36] [37] [38] [39] [40] [41] [42] Clinically, however, the duration of SCS is variable. For example, the duration of SCS has been reported as 6 to 8 sessions per day for 10 to 60 minutes each session and for longer periods between 5 and 12 hours in a single session. [43] [44] [45] The current study confirms that longer-duration SCS produces greater analgesia than shorter-duration SCS.
SCS Analgesia Can Persist After Stimulation
Previous work in a rat model of neuropathic pain (ligature of the sciatic nerve) shows 10 minutes of SCS attenuated allodynia for up to 40 minutes after cessation of the stimulation. 33 SCS also inhibited nociceptive discharges of dorsal horn neurons for approximately 30 to 40 minutes after the cessation of SCS. 46, 47 The current study extends these previous findings and shows a small yet significant reduction in mechanical hypersensitivity with 60 Hz SCS for up to 3 days after cessation of stimulation. Some previous studies also show that repeated SCS produces a cumulative analgesic effect. 19, 36, [48] [49] [50] In humans, how long the pain relief remains after SCS and which factors influence the duration of post-SCS pain relief is unknown. 43 Some authors suggest that the carryover and cumulative analgesic effect may involve a complex set of plastic changes and remodeling in spinal and supraspinal pain-processing structures. However, in the current and in our previous study, we were unable to show this cumulative analgesic effect with repeated stimulation. 43 
SCS Reduces Glial Cell Activation in the Spinal Cord
The current study showed for the first time that both 4 and 60 Hz SCS reduced microglia and astrocyte activation in the spinal cord in animals with neuropathic pain. Similarly, other therapeutic treatments that used our endogenous analgesia system also reduced glial activation, including electroacupuncture, peripheral nerve stimulation, and joint mobilization. [51] [52] [53] [54] SCS increases release of inhibitory neurotransmitters γ-aminobutyric acid, serotonin, acetylcholine, and opioids in the spinal dorsal horn, which could directly inhibit activation of glial cells. 16, 18, 31, 41, 55, 56 In fact, both astrocytes and microglia express inhibitory neurotransmitter receptors including GABAergic, serotonergic, and opioidergic receptors. [57] [58] [59] Alternatively, inhibitory neurotransmitters could indirectly reduce glial cell activity by reducing neuronal release of excitatory neurotransmitters. 60 It is well known that neuronal release of excitatory neurotransmitters such as glutamate are increased in response to nociceptive stimuli and that excitatory neurotransmitters can directly activate glial cells to perpetuate the nociceptive response. [61] [62] [63] [64] Therefore, further studies examining the underlying mechanisms of the reduced glial cell activity are required.
Glial cells have been implicated in producing hypersensitivity after nerve injury with both spinal microglia and astrocytes activated after nerve injury. 29, [65] [66] [67] [68] [69] [70] In the current study, we showed activation of both microglia and astrocytes after nerve injury with an early increase in phosphorylation of mitogen activated kinase p38, similar to previous studies. 29, 71, 72 However, our results showed that another microglial surface marker, CD11b (OX-42), continued to show enhanced immunoreactivity and that microglial cells appeared to remain activated 10 days to 2 weeks after nerve injury. 73, 74 The activation of astrocytes in the later phases also agrees with previous studies implicating these cells in the maintenance of mechanical allodynia in neuropathic pain. 75, 76 
CONCLUSION
In the present study, we examined stimulation variables and showed that the most effective analgesia was produced by 60 Hz SCS for 6-hour duration at 90% motor threshold. We further showed that SCS, both 4 and 60 Hz, reduces glial cell activation in the dorsal horn of the spinal cord. We suggest that SCS has the ability to modulate nociceptive input at the spinal cord using multiple inhibitory neurotransmitters that subsequently reduce glial cell activation. E DISCLOSURES Name: Karina L. Sato, PT, PhD. Contribution: This author helped design and conduct the study, collect data, analyze data, and prepare the manuscript. Attestation: Karina Sato attests to having approved the final manuscript and reviewed the original study data and data analysis. Karina Sato attests to the integrity of the original data and the analysis reported in this manuscript. Kathleen Sluka is designated as the archival author.
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